International Cancer Genome Consortium
Uk Cohort
Powered by SNPnexus
Overview
Help
Sex
Survival Status
Age at Diagnosis
Loading...
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| PDGFRA | PDGFRA MUT* (T281T) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ESR1 | ESR1 MUT* (intron_variant) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ERBB4 | ERBB4 MUT* (intron_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (intron_variant) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (intron_variant) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R248W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R248W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R248W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| AKT3 | AKT3 MUT* (intron_variant) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PML | PML MUT* (intron_variant) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (intron_variant) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| JAK2 | JAK2 MUT* (intron_variant) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| MET | MET MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | TP53 MUT (R213*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R213*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R213*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R213*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R213*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (intron_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (intron_variant) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BRD4 | BRD4 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (W53*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (W53*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (W53*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (W53*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (W53*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (W53*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (W53*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (W53*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCOR | BCOR MUT (S214*) | Complete Match | Enzastaurin (PKCb inhibitor) | Responsive | ST | Pre-clinical |
| PDGFRA | PDGFRA MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2D | MLL2 MUT (R5501*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| EGFR | EGFR MUT* (IntronicBlockSubstitution), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (IntronicBlockSubstitution), EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (intron_variant) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | NOTCH2 MUT* (Y1414Y), NOTCH2 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (intron_variant) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (intron_variant) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| CDH1 | CDH1 MUT (H29Rfs*27) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| ATM | ATM MUT (R2832C) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (R2832C) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (R2832C) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (R2832C) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R2832C) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R2832C) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R2832C) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (R2832C) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R2832C) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (R2832C) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (R2832C) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (R2832C) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (R2832C) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| PDGFB | PDGFB MUT* (3-UTRSNV), PDGFB MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | MTOR inhibitor | Responsive | ALL | Pre-clinical |
| CRLF2 | CRLF2 MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (splice_donor_variant) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_donor_variant) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (E17K) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| PDGFB | PDGFB MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| NTRK1 | NTRK1 MUT* (L641M) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (L641M) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (L641M) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (L641M) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (splice_acceptor_variant) | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | ATM MUT (splice_acceptor_variant) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ERBB4 | ERBB4 MUT (C193*) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CM | Pre-clinical |
| ERBB4 | ERBB4 MUT (C193*) | Different Mutation | ERBB2 inhibitor | Resistant | BRCA | Case report |
| ERBB4 | ERBB4 MUT (C193*) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D832H) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D832H) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (D832H) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (D832H) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (D832H) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (D832H) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (D832H) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (D832H) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (D832H) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D832H) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (D832H) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (D832H) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (D832H) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (D832H) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| CDH1 | CDH1 MUT (E494*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (3-UTRSNV), ALK MUT* (E1419K) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | SETD2 MUT (R2399*), SETD2 MUT (Q1164*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (R2399*), SETD2 MUT (Q1164*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| FGFR2 | FGFR2 MUT* (V396V) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (V396V) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| AKT3 | AKT3 MUT* (3-UTRSNV), AKT3 MUT* (intron_variant) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (3-UTRSNV) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E271Q) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E271Q) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E271Q) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E271Q) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E271Q) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E271Q) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E271Q) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E271Q) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (K111N), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ESR1 | ESR1 MUT* (3-UTRSNV), ESR1 MUT* (intron_variant) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant), NRG1 MUT* (L66L) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant), NRG1 MUT* (L66L) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| NOTCH2 | NOTCH2 MUT* (K1514R) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273P) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273P) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273P) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273P) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | ERBB4 MUT* (H295Q) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R806R) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R806R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (R806R) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R806R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (R806R) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (R806R) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R806R) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R806R) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (R806R) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R806R) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (R806R) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (R806R) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (R806R) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (R806R) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V274F) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V274F) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V274F) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274F) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V274D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (V274D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (V274D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (V274D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (V274D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (V274D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (V274D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (V274D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (V274D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (E522D), MLL MUT* (D431N) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E294*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E294*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E294*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E294*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E294*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FANCA | FANCA MUT (splice_acceptor_variant) | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Case report |
| FANCA | FANCA MUT (splice_acceptor_variant) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | PRAD | Case report |
| TP53 | TP53 MUT (Y163C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y163C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y163C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y163C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y163C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | MET MUT* (K306N) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PIK3CA | PIK3CA MUT (E545D) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545D) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545D) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (V499M) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PIK3CA | PIK3CA MUT (M1040T) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1040T) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1040T) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| SF3B1 | SF3B1 MUT (K700E) | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (T2074T) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (P338T) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (P338T) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Complete Match | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Complete Match | PARP inhibitor | Responsive | R, CANCER | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Complete Match | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Different Alteration | PARP inhibitor | Responsive | CANCER, R | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Different Alteration | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | BAP1 MUT (Q280*) | Different Alteration | HDAC inhibitor | Responsive | CM | Pre-clinical |
| FGFR2 | FGFR2 MUT* (5-UTRSNV) | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | FGFR2 MUT* (5-UTRSNV) | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | TP53 MUT (F270L) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (F270L) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (F270L) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (F270L) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (F270L) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (F270L) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (F270L) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (F270L) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (F270L) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C141Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C141Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C141Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| STAG2 | STAG2 MUT (L588*) | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G245S) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G245S) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G245S) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245S) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H179Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H179Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H179Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| APC | APC MUT (R1463*) | Complete Match | Tankyrase inhibitor | Responsive | COREAD | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R306*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R306*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R306*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R306*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | NOTCH1 MUT* (W861C) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (W861C) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q192*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q192*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q192*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q192*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y234C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y234C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y234C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EPHA2 | EPHA2 MUT (E825*) | Different Mutation | MTOR inhibitor | Responsive | LUSC | Pre-clinical |
| EPHA2 | EPHA2 MUT (E825*) | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | LUSC | Pre-clinical |
| EPHA2 | EPHA2 MUT (E825*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB4 | ERBB4 MUT* (R711C) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043V) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (M1043V) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (M1043V) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (Y2076*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Y2076*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Y2076*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Y2076*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y27D) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Y27D) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Y27D) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y27D) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y27D) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y27D) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Y27D) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y27D) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y27D) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y27D) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y27D) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Y27D) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Y27D) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Y27D) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Y27D) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Y27D) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Y27D) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Y27D) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Y27D) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y236C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y236C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y236C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y236C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y236C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y236C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y236C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y236C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (N345K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (N345K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ARID1A | ARID1A MUT (Y1285Lfs*2) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Y1285Lfs*2) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Y1285Lfs*2) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Y1285Lfs*2) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (G1049R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (G1049R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | ROS1 MUT* (E163E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (E163E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (E163E) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (E163E) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (E163E) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C275Y) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C275Y) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C275Y) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDK12 | CDK12 MUT (E1198*) | Complete Match | PARP inhibitor | Responsive | OV | Pre-clinical |
| CDK12 | CDK12 MUT (E1198*) | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E81K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E81K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R248Q) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R248Q) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R248Q) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R248Q) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATR | ATR MUT (K704*) | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | ATR MUT (K704*) | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | ATR MUT (K704*) | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| POLE | POLE MUT (splice_acceptor_variant) | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| POLE | POLE MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | COREAD | Case report |
| POLE | POLE MUT (splice_acceptor_variant) | Different Mutation | PD1 Ab inhibitor | Responsive | G, ED | Case report |
| POLE | POLE MUT (splice_acceptor_variant) | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| CDH1 | CDH1 MUT (Q448*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| AKT1 | AKT1 MUT (Q79K) | Complete Match | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (Q79K) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (P104L), PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (C23W) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| TP53 | TP53 MUT (E286K) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E286K) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E286K) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E286K) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E286K) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q317*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q317*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q317*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q317*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q317*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q317*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q317*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q317*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q317*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (splice_acceptor_variant) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (L52R) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (Q546K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (Q546K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E545A) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E545A) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | ERBB4 MUT* (P1153H) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R273C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R273C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R273C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R273C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (Q17*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q17*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q17*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Q17*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q17*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q17*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q17*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Q17*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q17*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q17*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q17*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q17*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q17*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q17*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q17*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q17*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q17*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q17*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q17*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q17*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (D297Y) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| CDH1 | CDH1 MUT (Y523*) | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | PDGFRA MUT* (F178S) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ARID1A | ARID1A MUT (K1010*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (K1010*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (K1010*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (K1010*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | ERBB3 MUT (V104L) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| TP53 | TP53 MUT (E204*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E204*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E204*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E204*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E204*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MSH3 | MSH3 MUT (K813*) | Complete Match | DNA-PKc inhibitor | Responsive | CANCER | Pre-clinical |
| BRAF | BRAF MUT* (R671Q) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (R671Q) | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | BRAF MUT* (R671Q) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | BRAF MUT* (R671Q) | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L993L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (L993L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (L993L) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (L993L) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (L993L) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12A) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | KRAS MUT (G12A) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12A) | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | KRAS MUT (G12A) | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | KRAS MUT (G12A) | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | KRAS MUT (G12A) | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | KRAS MUT (G12A) | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | KRAS MUT (G12A) | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | KRAS MUT (G12A) | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | KRAS MUT (G12A) | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | KRAS MUT (G12A) | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| ROS1 | ROS1 MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (5-UTRSNV) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (5-UTRSNV) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (5-UTRSNV) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | TP53 MUT (H179R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H179R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H179R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H179R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H179R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G245C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G245C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G245C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G245C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G245C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G245C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G245C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G245C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (I32S) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (I32S) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (I32S) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (I32S) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (I32S) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (I32S) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (I32S) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (I32S) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (I32S) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (I32S) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (I32S) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (I32S) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (I32S) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (I32S) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (I32S) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (I32S) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (I32S) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (I32S) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (I32S) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (I32S) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (E2143Q) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R196*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R196*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R196*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R196*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | MET MUT* (intron_variant), MET MUT* (R412C) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| AKT3 | AKT3 MUT* (intron_variant), AKT3 MUT* (3-UTRSNV) | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (splice_acceptor_variant) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | RB1 MUT (splice_acceptor_variant) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (splice_acceptor_variant) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_acceptor_variant) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_acceptor_variant) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_acceptor_variant) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (splice_acceptor_variant) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (splice_acceptor_variant) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| NOTCH2 | NOTCH2 MUT* (G864D), NOTCH2 MUT* (C616Y) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R282W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R282W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R282W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R282W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (splice_acceptor_variant) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | NOTCH2 MUT (Q2317*) | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | NOTCH2 MUT (Q2317*) | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | NOTCH2 MUT (Q2317*) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G262V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G262V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G262V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G262V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G262V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G262V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G262V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G262V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | NF1 MUT (L1801*) | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | NF1 MUT (L1801*) | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | NF1 MUT (L1801*) | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (S241A) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (S241A) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (S241A) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (S241A) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (S241A) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (S241A) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (S241A) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (S241A) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R175H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R175H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTPRD | PTPRD MUT (Y990*) | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| NOTCH2 | NOTCH2 MUT* (3-UTRSNV) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H193R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H193R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | RB1 MUT (R556*) | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | RB1 MUT (R556*) | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R556*) | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R556*) | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R556*) | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | RB1 MUT (R556*) | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | RB1 MUT (R556*) | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (intron_variant), RET MUT* (L760L) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (intron_variant), BCR MUT* (E211E) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| TP53 | TP53 MUT (Y234*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y234*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y234*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y234*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y234*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y234*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y234*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y234*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y234*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FAT1 | FAT1 MUT (Q906*) | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| FOXA1 | FOXA1 MUT (Q23*) | Different Alteration | BCL2 inhibitor | Responsive | COREAD | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G266E) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G266E) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G266E) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G266E) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PDGFRA | PDGFRA MUT* (R383H) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (intron_variant), MLL MUT* (IntronicBlockSubstitution) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ESR1 | ESR1 MUT* (intron_variant), ESR1 MUT* (IntronicBlockSubstitution) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (E258D) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (E258D) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (E258D) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (E258D) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (E258D) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (E258D) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (E258D) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (E258D) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | PTEN MUT (Q245*) | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q245*) | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | PTEN MUT (Q245*) | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | PTEN MUT (Q245*) | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q245*) | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q245*) | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q245*) | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | PTEN MUT (Q245*) | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q245*) | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q245*) | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q245*) | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q245*) | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | PTEN MUT (Q245*) | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | PTEN MUT (Q245*) | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | PTEN MUT (Q245*) | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | PTEN MUT (Q245*) | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | PTEN MUT (Q245*) | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | PTEN MUT (Q245*) | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | PTEN MUT (Q245*) | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | PTEN MUT (Q245*) | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (M237I) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (M237I) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (M237I) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (M237I) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | ROS1 MUT* (Y1408C) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (Y1408C) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (Y1408C) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (Y1408C) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (Y1408C) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | ERBB4 MUT* (3-UTRSNV), ERBB4 MUT* (intron_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (R189H) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (R189H) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R189H) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (R189H) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R189H) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (R189H) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R189H) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R189H) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (R189H) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| NOTCH2 | NOTCH2 MUT (E2266*) | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | NOTCH2 MUT (E2266*) | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | NOTCH2 MUT* (E2261E), NOTCH2 MUT* (W2253C), NOTCH2 MUT* (intron_variant), NOTCH2 MUT* (K2132K), NOTCH2 MUT (E2266*) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EPHA3 | EPHA3 MUT (E264*) | Different Alteration | EPHA3 inhibitor | Responsive | CANCER | Pre-clinical |
| ESR1 | ESR1 MUT* (intron_variant), ESR1 MUT* (A283V) | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Loading...
Drug-Gene Interactions help
Druggable categories in the cohort
No meaningful categories found
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| PIK3CA | MyCancerGenome | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | CKB | MS417 | |||
| PIK3CA | CIViC | RAPAMYCIN (SIROLIMUS) | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CGI | Chemotherapy | |||
| PIK3CA | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | HS-173 | ||
| PIK3CA | CKB | Linsitinib | LINSITINIB | CHEMBL1091644 | |
| PIK3CA | CKB | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AMG319 | AMG-319 | CHEMBL3545048 |
| PIK3CA | MyCancerGenome | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | ClearityFoundationBiomarkers | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | NCI | I3C | INDOLE-3-CARBINOL | CHEMBL155625 | |
| PIK3CA | CKB | GDC-0941 | PICTILISIB | CHEMBL521851 | |
| PIK3CA | CKB | Navitoclax | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CIViC | PICTILISIB | PICTILISIB | CHEMBL521851 | |
| PIK3CA | ChemblInteractions | inhibitor | SF-1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | ClearityFoundationBiomarkers | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | GuideToPharmacologyInteractions | allosteric modulator | PIK-108 | ||
| PIK3CA | CKB | Neratinib | NERATINIB | CHEMBL180022 | |
| PIK3CA | CGI | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8186 | AZD-8186 | CHEMBL3545424 |
| PIK3CA | CKB | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | OncoKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | SERM | |||
| PIK3CA | CKB | ASN003 | |||
| PIK3CA | CIViC | PP242 | |||
| PIK3CA | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| PIK3CA | CIViC | BYL719 (ALPELISIB) | |||
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | CKB | GDC-0980 | APITOLISIB | CHEMBL1922094 | |
| PIK3CA | CKB | Radiotherapy | |||
| PIK3CA | CKB | Palbociclib | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | LY2780301 | LY-2780301 | CHEMBL3545134 | |
| PIK3CA | NCI | RAS INHIBITOR | |||
| PIK3CA | OncoKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | HGF | |||
| PIK3CA | CIViC | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CKB | Tamoxifen | TAMOXIFEN | CHEMBL83 | |
| PIK3CA | CKB | Trametinib | TRAMETINIB | CHEMBL2103875 | |
| PIK3CA | NCI | RAPAMYCIN | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | TGX-221 | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0032 | TASELISIB | CHEMBL2387080 |
| PIK3CA | ChemblInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33587 | PWT-33587 | CHEMBL3545006 |
| PIK3CA | ChemblInteractions | inhibitor | RECILISIB | RECILISIB | CHEMBL2219421 |
| PIK3CA | CIViC | CETUXIMAB | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | CIViC | LAPATINIB | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | CUDC-907 | CUDC-907 | CHEMBL3545052 | |
| PIK3CA | CKB | VS-5584 | VS-5584 | CHEMBL1079593 | |
| PIK3CA | CKB | Lapatinib | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | Selumetinib | SELUMETINIB | CHEMBL1614701 | |
| PIK3CA | CKB | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | NCI | SELECTIVE ESTROGEN RECEPTOR MODULATOR | |||
| PIK3CA | OncoKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | CKB | GSK1059615 | GSK-1059615 | CHEMBL3544966 | |
| PIK3CA | ChemblInteractions | inhibitor | PA-799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CKB | ARQ092 | ARQ-092 | CHEMBL3545422 | |
| PIK3CA | CKB | BGJ398 | INFIGRATINIB | CHEMBL1852688 | |
| PIK3CA | ChemblInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | MyCancerGenome | inhibitor | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 |
| PIK3CA | ChemblInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | OncoKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | TdgClinicalTrial | RIGOSERTIB | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | CKB | Cisplatin | |||
| PIK3CA | ChemblInteractions | inhibitor | COPANLISIB | COPANLISIB | CHEMBL3218576 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR II | CHEMBL1231533 | CHEMBL1231533 |
| PIK3CA | CIViC | PERIFOSINE | PERIFOSINE | CHEMBL372764 | |
| PIK3CA | ChemblInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | ChemblInteractions | inhibitor | SONOLISIB | SONOLISIB | CHEMBL411907 |
| PIK3CA | ChemblInteractions | inhibitor | PKI-179 | PKI-179 | CHEMBL1258517 |
| PIK3CA | MyCancerGenome | inhibitor | GDC-0980 | APITOLISIB | CHEMBL1922094 |
| PIK3CA | CKB | Demcizumab | DEMCIZUMAB | CHEMBL2109384 | |
| PIK3CA | NCI | FLAVOPIRIDOL | ALVOCIDIB | CHEMBL428690 | |
| PIK3CA | NCI | PKC412 | MIDOSTAURIN | CHEMBL608533 | |
| PIK3CA | ChemblInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | P7170 | Panulisib | CHEMBL3545322 | |
| PIK3CA | ClearityFoundationBiomarkers | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | CKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | CancerCommons | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | OncoKB | Serabelisib | YOHIMBINE | CHEMBL15245 | |
| PIK3CA | ChemblInteractions | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | NCI | IL-2 | |||
| PIK3CA | CKB | Bevacizumab | BEVACIZUMAB | CHEMBL1201583 | |
| PIK3CA | MyCancerGenome | inhibitor | GSK2636771 | GSK-2636771 | CHEMBL3188551 |
| PIK3CA | CKB | PKI-179 | PKI-179 | CHEMBL1258517 | |
| PIK3CA | ClearityFoundationBiomarkers | BAY80-6946 | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | CIViC | PALBOCICLIB (PD0332991) | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | Idelalisib | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | ChemblInteractions | inhibitor | LY-3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | CIViC | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CIViC | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | THEAFLAVINS | |||
| PIK3CA | CIViC | IDELALISIB | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | NCI | PTHRP | |||
| PIK3CA | CKB | GSK2334470 | CHEMBL1765740 | CHEMBL1765740 | |
| PIK3CA | CKB | Doxil | |||
| PIK3CA | CIViC | CISPLATIN | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY 294002 | LY-294002 | CHEMBL98350 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ECF309 | ||
| PIK3CA | ClearityFoundationBiomarkers | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | ClearityFoundationBiomarkers | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | NCI | RALOXIFENE | RALOXIFENE | CHEMBL81 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PIK-75 | ||
| PIK3CA | ChemblInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | Ponatinib | PONATINIB | CHEMBL1171837 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CH5132799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CIViC | ANTI-EGFR MONOCLONAL ANTIBODY | |||
| PIK3CA | ClearityFoundationBiomarkers | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | BAY1125976 | BAY-1125976 | CHEMBL3545049 | |
| PIK3CA | CKB | Sirolimus | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | GSK2141795 | UPROSERTIB | CHEMBL3137336 | |
| PIK3CA | MyCancerGenome | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | CKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | ChemblInteractions | inhibitor | RG-7666 | RG-7666 | CHEMBL3545324 |
| PIK3CA | CKB | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | LY294002 | LY-294002 | CHEMBL98350 | |
| PIK3CA | CKB | AT-7867 | CHEMBL428462 | CHEMBL428462 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BGT-226 | ||
| PIK3CA | NCI | SULINDAC | SULINDAC | CHEMBL15770 | |
| PIK3CA | NCI | CAMPTOTHECIN | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | CKB | WEHI-539 | |||
| PIK3CA | CKB | GDC-0032 | TASELISIB | CHEMBL2387080 | |
| PIK3CA | CKB | Fluorouracil | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | MyCancerGenome | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | ChemblInteractions | inhibitor | ZSTK-474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CancerCommons | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | YM-024 | |||
| PIK3CA | CKB | PKI-402 | CHEMBL589258 | CHEMBL589258 | |
| PIK3CA | CIViC | PI3K INHIBITOR | |||
| PIK3CA | ChemblInteractions | inhibitor | BGT-226 | BGT-226 (CHEMBL3545096) | CHEMBL3545096 |
| PIK3CA | CKB | Vistusertib | BENZONATATE | CHEMBL1374379 | |
| PIK3CA | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LENIOLISIB | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PQR309 | ||
| PIK3CA | TdgClinicalTrial | SF1126 | SF-1126 | CHEMBL2326966 | |
| PIK3CA | CKB | FOLFOX | |||
| PIK3CA | CKB | rigosertib | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | NCI | STZ | STREPTOZOTOCIN | CHEMBL1651906 | |
| PIK3CA | NCI | HERBIMYCIN A | HERBIMYCIN | CHEMBL479533 | |
| PIK3CA | CKB | Sapanisertib | INK-128 | CHEMBL3545056 | |
| PIK3CA | CKB | A-443654 | A-443654 | CHEMBL379300 | |
| PIK3CA | CKB | AZD8055 | AZD-8055 | CHEMBL1801204 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8835 | CANDICIDIN | CHEMBL1200647 |
| PIK3CA | MyCancerGenome | inhibitor | XL-765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | OncoKB | Taselisib | TASELISIB | CHEMBL2387080 | |
| PIK3CA | OncoKB | Ribociclib | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | GSK-1059615 | GSK-1059615 | CHEMBL3544966 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 28 [PMID: 24387221] | ||
| PIK3CA | CKB | Pertuzumab | PERTUZUMAB | CHEMBL2007641 | |
| PIK3CA | MyCancerGenome | inhibitor | SF1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | CKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | CKB | OSI-027 | OSI-027 | CHEMBL3120215 | |
| PIK3CA | ChemblInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | ChemblInteractions | inhibitor | VOXTALISIB | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ZSTK474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TG-100-115 | TG100-115 | CHEMBL230011 |
| PIK3CA | CKB | PI-103 | PI-103 | CHEMBL573339 | |
| PIK3CA | MyCancerGenome | inhibitor | PWT33597 | ||
| PIK3CA | NCI | PACLITAXEL | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | CKB | U0126 | U-0126 | CHEMBL100473 | |
| PIK3CA | CIViC | RADIATION | |||
| PIK3CA | CKB | Lucitanib | LUCITANIB | CHEMBL2220486 | |
| PIK3CA | OncoKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | CKB | Torin 1 | TORIN1 | CHEMBL1256459 | |
| PIK3CA | CKB | Carboxyamidotriazole Orotate | |||
| PIK3CA | CKB | ARQ 751 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | AZD8835 | CANDICIDIN | CHEMBL1200647 | |
| PIK3CA | CKB | 5-FU | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | ClearityFoundationBiomarkers | XL-147 | |||
| PIK3CA | NCI | RESVERATROL | RESVERATROL | CHEMBL165 | |
| PIK3CA | CKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | GSK2126458 | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | SAR245409 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | ABT-263 | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CKB | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | MyCancerGenome | inhibitor | BGJ398 | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | CancerCommons | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | NVP-AEW541 | AEW-541 | CHEMBL551064 | |
| PIK3CA | CIViC | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | BKM120 | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | OncoKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CIViC | BEZ235 (NVP-BEZ235, DACTOLISIB) | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | DS-7423 | DS-7423 | CHEMBL3545248 |
| PIK3CA | CKB | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | CKB | Regorafenib | REGORAFENIB | CHEMBL1946170 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | SERABELISIB | YOHIMBINE | CHEMBL15245 |
| PIK3CA | CGI | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PP121 | CHEMBL1081312 | CHEMBL1081312 |
| PIK3CA | CKB | Temsirolimus | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | A-1210477 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IDELALISIB | IDELALISIB | CHEMBL2216870 |
| PIK3CA | CKB | MLN1117 | INK-1117 | CHEMBL3545055 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | KU-0060648 | CHEMBL1086377 | CHEMBL1086377 |
| PIK3CA | NCI | DHEA | PRASTERONE | CHEMBL90593 | |
| PIK3CA | CKB | Dabrafenib | DABRAFENIB | CHEMBL2028663 | |
| PIK3CA | NCI | UROKINASE-TYPE PLASMINOGEN ACTIVATOR | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 11J [PMID: 23021994] | ||
| PIK3CA | ChemblInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | Ridaforolimus | RIDAFOROLIMUS | CHEMBL2103839 | |
| PIK3CA | MyCancerGenome | inhibitor | PF-4691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | CKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | BCG | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | OncoKB | LJM716 | |||
| PIK3CA | OncoKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | NCI | 17-AAG | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | NCI | NSAID | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0941 | PICTILISIB | CHEMBL521851 |
| PIK3CA | ChemblInteractions | inhibitor | AZD-6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | WORTMANNIN | WORTMANNIN | CHEMBL428496 |
| PIK3CA | CKB | GS-9820 | Acalisib | CHEMBL3545397 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | NEMIRALISIB | ||
| PIK3CA | CKB | Torkinib | |||
| PIK3CA | CKB | PD-0325901 | PD-0325901 | CHEMBL507361 | |
| PIK3CA | CKB | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| PIK3CA | CKB | Deguelin | DEGUELIN | CHEMBL393417 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | INK-128 | INK-128 | CHEMBL3545056 |
| PIK3CA | CKB | Dasatinib | DASATINIB | CHEMBL1421 | |
| PIK3CA | CancerCommons | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | TRAIL | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR | CHEMBL568150 | CHEMBL568150 |
| PIK3CA | NCI | GM-CSF | REGRAMOSTIM | CHEMBL2107881 | |
| PIK3CA | MyCancerGenome | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | CKB | CCT128930 | CHEMBL263664 | CHEMBL263664 | |
| PIK3CA | TdgClinicalTrial | PWT33597 | |||
| PIK3CA | NCI | ZINC SULFATE | ZINC SULFATE | CHEMBL1200929 | |
| PIK3CA | CKB | trastuzumab emtansine | TRASTUZUMAB EMTANSINE | CHEMBL1743082 | |
| PIK3CA | CKB | A66 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | OncoKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | MyCancerGenome | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | MyCancerGenome | inhibitor | SOPHORETIN | QUERCETIN | CHEMBL50 |
| PIK3CA | CKB | BAY1082439 | BAY-1082439 | CHEMBL3545245 | |
| PIK3CA | CIViC | TRASTUZUMAB | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | NCI | CARBOPLATIN | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | NCI | ANTIANGIOGENIC | |||
| PIK3CA | MyCancerGenome | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | WYE-125132 | |||
| PIK3CA | OncoKB | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CIViC | CABOZANTINIB | CABOZANTINIB | CHEMBL2105717 | |
| PIK3CA | NCI | VINCRISTINE | VINCRISTINE | CHEMBL90555 | |
| PIK3CA | NCI | DOXORUBICIN | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | BAY-1082439 | BAY-1082439 | CHEMBL3545245 |
| PIK3CA | CKB | Afuresertib | AFURESERTIB | CHEMBL2219422 | |
| PIK3CA | CancerCommons | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Floxuridine | FLOXURIDINE | CHEMBL917 | |
| PIK3CA | CancerCommons | inhibitor | XL765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | ClearityFoundationBiomarkers | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | NCI | RETINOID | ETRETINATE | CHEMBL464 | |
| PIK3CA | CKB | DHM25 | |||
| PIK3CA | CKB | Gedatolisib | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | PWT33597 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 82 [PMID: 21332118] | ||
| PIK3CA | CKB | Camptothecin | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | ChemblInteractions | inhibitor | WX-037 | WX-037 | CHEMBL3545385 |
| PIK3CA | CKB | Venetoclax | VENETOCLAX | CHEMBL3137309 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | QUINOSTATIN | ||
| PIK3CA | NCI | TYROSINE KINASE INHIBITORS | |||
| PIK3CA | ChemblInteractions | inhibitor | Puquitinib | Puquitinib | CHEMBL3545088 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33579 | PWT-33579 | CHEMBL3545323 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BUPARLISIB HYDROCHLORIDE | BUPARLISIB HYDROCHLORIDE | CHEMBL2364604 |
| PIK3CA | CKB | ABT-737 | CHEMBL376408 | CHEMBL376408 | |
| PIK3CA | CIViC | PANITUMUMAB | PANITUMUMAB | CHEMBL1201827 | |
| PIK3CA | ChemblInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 | |
| PIK3CA | CIViC | MK-2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IPI549 | OXAZEPAM | CHEMBL568 |
| PIK3CA | CKB | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | ChemblInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CKB | MK2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | ChemblInteractions | inhibitor | Panulisib | Panulisib | CHEMBL3545322 |
| PIK3CA | CKB | PD98509 | |||
| PIK3CA | CancerCommons | inhibitor | SAR260301 | SAR-260301 | CHEMBL3545008 |
| PIK3CA | CKB | Metformin | METFORMIN | CHEMBL1431 | |
| PIK3CA | CKB | Vemurafenib | VEMURAFENIB | CHEMBL1229517 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | SURAMIN | SURAMIN | CHEMBL265502 | |
| PIK3CA | CKB | Capecitabine | CAPECITABINE | CHEMBL1773 | |
| PIK3CA | ClearityFoundationBiomarkers | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | ClearityFoundationBiomarkers | NVP-BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | CKB | Pimasertib | PIMASERTIB | CHEMBL2107832 | |
| PIK3CA | MyCancerGenome | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CIViC | TASELISIB (GDC-0032) | |||
| PIK3CA | NCI | MILTEFOSINE | MILTEFOSINE | CHEMBL125 | |
| PIK3CA | NCI | QUERCETIN | QUERCETIN | CHEMBL50 | |
| PIK3CA | CGI | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | TdgClinicalTrial | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | AT13148 | AT-13148 | CHEMBL3544960 | |
| PIK3CA | ChemblInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| PIK3CA | CKB | CGM097 | |||
| PIK3CA | CKB | MSC2363318A | MSC-2363318A | CHEMBL3545003 | |
| PIK3CA | CKB | PW12 | |||
| PIK3CA | NCI | 17-ALLYL-AMINOGELDANAMYCIN | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 |
| PIK3CA | CKB | CC-223 | CC-223 | CHEMBL3545151 | |
| PIK3CA | CKB | cobimetinib | COBIMETINIB | CHEMBL2146883 | |
| PIK3CA | NCI | CPT-11 | IRINOTECAN | CHEMBL481 | |
| PIK3CA | OncoKB | Buparlisib | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | NCI | IL-11 | |||
| PIK3CA | CKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | OncoKB | ASN003 | |||
| PIK3CA | CKB | Sorafenib | SORAFENIB | CHEMBL1336 | |
| PIK3CA | CKB | PF-4989216 | |||
| PIK3CA | CKB | TAK-733 | TAK-733 | CHEMBL1615025 | |
| PIK3CA | CKB | LY3023414 | LY-3023414 | CHEMBL3544999 | |
| PIK3CA | CKB | PX-866 | SONOLISIB | CHEMBL411907 | |
| PIK3CA | CKB | Bortezomib | BORTEZOMIB | CHEMBL325041 | |
| PIK3CA | CKB | Carboplatin | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | ChemblInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | OncoKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | CKB | Ipatasertib | IPATASERTIB | CHEMBL2177390 | |
| PIK3CA | ClearityFoundationBiomarkers | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CKB | Topotecan | TOPOTECAN | CHEMBL84 | |
| PIK3CA | CIViC | RIBOCICLIB | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | MLN-1117 | MLN-1117 | CHEMBL3545379 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DUVELISIB | DUVELISIB | CHEMBL3039502 |
Phenotype
Protein
DrugThere are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.
Researchers can request samples from BCNB website to support their research activities.
*Based on your filtering criteria you can view the number of available patients and associated samples in BCNBIn order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.
If you require further details please contact us at tissue.bank@breastcancernow.org
| Patient ID | Age at Diagnosis | Sex | Family History | Tumour Stage | Survival Status |
|---|---|---|---|---|---|
| DO1000 | 61.0 | female | no | T2N1M0 | alive |
| DO1001 | 41.0 | female | NA | NA | NA |
| DO1002 | 39.0 | female | yes | T1b_pN0(sn)_MX | alive |
| DO1003 | 34.0 | female | yes | pT1N0M0 | alive |
| DO1004 | 59.0 | female | yes | pT2N1Mx | deceased |
| DO1005 | 39.0 | female | yes | pT2N0M0 | alive |
| DO1006 | 39.0 | female | yes | pT2N0M0 | deceased |
| DO1007 | 64.0 | female | yes | T2pN0MX | alive |
| DO1008 | 58.0 | female | yes | T2pN1BivMX | deceased |
| DO1009 | 32.0 | female | yes | T2pN1MX | alive |
| DO1010 | 67.0 | female | NA | T2pN0MX | NA |
| DO1011 | 54.0 | female | NA | T2N1 | NA |
| DO1012 | 32.0 | female | NA | T2N0 | NA |
| DO1013 | NA | female | NA | pT1cN0 | NA |
| DO1014 | NA | female | yes | pT1cNoMx | NA |
| DO1015 | NA | female | NA | NA | NA |
| DO1016 | NA | female | NA | NA | NA |
| DO1017 | 49.0 | female | yes | NA | deceased |
| DO1018 | 46.0 | female | NA | pT2N1M0 | NA |
| DO1020 | 33.0 | female | NA | pT2N0M0 | NA |
| DO1022 | NA | female | NA | NA | NA |
| DO1024 | NA | female | NA | NA | NA |
| DO1026 | NA | female | NA | NA | NA |
| DO1028 | NA | female | NA | NA | NA |
| DO1030 | NA | female | NA | NA | NA |
| DO1032 | NA | female | NA | NA | NA |
| DO1034 | NA | female | NA | NA | NA |
| DO1036 | NA | female | NA | NA | NA |
| DO1038 | NA | female | NA | NA | NA |
| DO1069 | NA | female | NA | NA | NA |
| DO1071 | NA | female | NA | NA | NA |
| DO1073 | NA | female | NA | NA | NA |
| DO1075 | NA | female | NA | NA | NA |
| DO1076 | NA | female | NA | NA | NA |
| DO1078 | NA | female | NA | NA | NA |
| DO1080 | NA | female | NA | NA | NA |
| DO1082 | NA | female | NA | NA | NA |
| DO1083 | NA | female | NA | NA | NA |
| DO1085 | NA | female | NA | NA | NA |
| DO1087 | NA | female | NA | NA | NA |
| DO1088 | NA | female | NA | NA | NA |
| DO1090 | NA | female | NA | NA | NA |
| DO1092 | NA | female | NA | NA | NA |
| DO1094 | NA | female | NA | NA | NA |
| DO1096 | NA | female | NA | NA | NA |
| DO1098 | NA | female | NA | NA | NA |
| DO1100 | NA | female | NA | NA | NA |
| DO1101 | NA | female | NA | NA | NA |
| DO1103 | NA | female | NA | NA | NA |
| DO1105 | NA | female | NA | NA | NA |
| DO1106 | NA | female | NA | NA | NA |
| DO1108 | NA | female | NA | NA | NA |
| DO1110 | NA | female | NA | NA | NA |
| DO1112 | NA | female | NA | NA | NA |
| DO1114 | NA | female | NA | NA | NA |
| DO1116 | NA | female | NA | NA | NA |
| DO1118 | NA | female | NA | NA | NA |
| DO1120 | NA | female | NA | NA | NA |
| DO1121 | NA | female | NA | NA | NA |
| DO1123 | NA | female | NA | NA | NA |
| DO1125 | NA | female | NA | NA | NA |
| DO1127 | NA | female | NA | NA | NA |
| DO1128 | NA | female | NA | NA | NA |
| DO1129 | NA | female | NA | NA | NA |
| DO1131 | NA | female | NA | NA | NA |
| DO1132 | NA | female | NA | NA | NA |
| DO1134 | NA | female | NA | NA | NA |
| DO1136 | NA | female | NA | NA | NA |
| DO1138 | NA | female | NA | NA | NA |
| DO1140 | NA | female | NA | NA | NA |
| DO1142 | NA | female | NA | NA | NA |
| DO1144 | NA | female | NA | NA | NA |
| DO1146 | NA | female | NA | NA | NA |
| DO1148 | NA | female | NA | NA | NA |
| DO1150 | NA | female | NA | NA | NA |
| DO1151 | NA | female | NA | NA | NA |
| DO1153 | NA | female | NA | NA | NA |
| DO1155 | NA | female | NA | NA | NA |
| DO1156 | NA | female | NA | NA | NA |
| DO1158 | NA | female | NA | NA | NA |
| DO1160 | NA | female | NA | NA | NA |
| DO1162 | NA | female | NA | NA | NA |
| DO1164 | NA | female | NA | NA | NA |
| DO1166 | NA | female | NA | NA | NA |
| DO1168 | NA | female | NA | NA | NA |
| DO1170 | NA | female | NA | NA | NA |
| DO1172 | NA | female | NA | NA | NA |
| DO1174 | NA | female | NA | NA | NA |
| DO1175 | NA | female | NA | NA | NA |
| DO1177 | NA | female | NA | NA | NA |
| DO1179 | NA | female | NA | NA | NA |
| DO1181 | NA | female | NA | NA | NA |
| DO1183 | NA | female | NA | NA | NA |
| DO1185 | NA | female | NA | NA | NA |
| DO1187 | NA | female | NA | NA | NA |
| DO1189 | NA | female | NA | NA | NA |
| DO1191 | NA | female | NA | NA | NA |
| DO1193 | NA | female | NA | NA | NA |
| DO1195 | NA | female | NA | NA | NA |
| DO1197 | NA | female | NA | NA | NA |
| DO1199 | NA | female | NA | NA | NA |
| DO1200 | NA | female | NA | NA | NA |
| DO1201 | NA | female | NA | NA | NA |
| DO1203 | NA | female | NA | NA | NA |
| DO1205 | NA | female | NA | NA | NA |
| DO1207 | NA | female | NA | NA | NA |
| DO1209 | NA | female | NA | NA | NA |
| DO1211 | NA | female | NA | NA | NA |
| DO1213 | NA | female | NA | NA | NA |
| DO1215 | NA | female | NA | NA | NA |
| DO1217 | NA | female | NA | NA | NA |
| DO1219 | NA | female | NA | NA | NA |
| DO1221 | NA | female | NA | NA | NA |
| DO1223 | NA | female | NA | NA | NA |
| DO1225 | NA | female | NA | NA | NA |
| DO1227 | NA | female | NA | NA | NA |
| DO1229 | NA | female | NA | NA | NA |
| DO1231 | NA | female | NA | NA | NA |
| DO1233 | NA | female | NA | NA | NA |
| DO1235 | NA | female | NA | NA | NA |
| DO1237 | NA | female | NA | NA | NA |
| DO1239 | NA | female | NA | NA | NA |
| DO1241 | NA | female | NA | NA | NA |
| DO1243 | NA | female | NA | NA | NA |
| DO1245 | NA | female | NA | NA | NA |
| DO1247 | NA | female | NA | NA | NA |
| DO52538 | 59.0 | female | no | NA | deceased |
| DO52539 | 39.0 | female | yes | T2pN0MX | NA |
| DO52540 | 52.0 | female | yes | T2N1M0 | deceased |
| DO52541 | 41.0 | female | NA | T1N0M0 | alive |
| DO52542 | 61.0 | female | NA | T1N0M0 | alive |
| DO52543 | 56.0 | female | NA | T1N0M0 | alive |
| DO52544 | 43.0 | female | NA | pT1cpN0M0 | NA |
| DO52545 | 64.0 | female | NA | pT1bpN0M0 | NA |
| DO52546 | 65.0 | female | NA | pT2pN0Mx | NA |
| DO52547 | NA | female | NA | NA | NA |
| DO52548 | 41.0 | female | NA | T2N0M0 | alive |
| DO52549 | 79.0 | female | yes | T2N0M0 | alive |
| DO52550 | 46.0 | female | NA | ll | alive |
| DO52551 | 36.0 | female | NA | ll | alive |
| DO52552 | 62.0 | female | NA | l | alive |
| DO52553 | 30.0 | female | yes | pT1N0M0 | alive |
| DO52554 | 46.0 | female | yes | T1N1M0 | alive |
| DO52555 | 68.0 | female | NA | T1N1M0 | alive |
| DO52556 | 56.0 | female | no | T2N2M0 | alive |
| DO52557 | 41.0 | female | NA | T1N0M0 | alive |
| DO52558 | 43.0 | female | NA | NA | alive |
| DO52559 | 42.0 | female | yes | pT2N0 | alive |
| DO52560 | 70.0 | female | yes | I | alive |
| DO52561 | 75.0 | female | NA | pT1cN0Mx | NA |
| DO52562 | 49.0 | female | NA | T2N1M0 | alive |